

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3860)

REDUCTION IN LOSS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023

This announcement is made by EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2023 (“**Period**”) and other information currently available to the Board, the Group expects to record a loss of approximately HKD4 million for the Period, as compared to a loss of approximately HKD20 million for the corresponding period in 2022. The expected reduction in loss was mainly attributable to the gain on revaluation of the promissory note issued for the acquisition of the 65% equity interests in R&E Corporation Limited, the details of which are set out in the announcement of the Company dated 28 March 2023, for the Period.

As the Company is still in the process of finalising the consolidated results for the Period, the information contained in this announcement is only based on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the Period and the information currently available, which is not audited or reviewed by the Company’s auditors or the audit committee, and the information is subject to any adjustment and finalisation. Therefore, the actual interim results of the Group for the Period may differ from the information contained in this announcement. Further details of the Group’s financial results and performance will be disclosed in the Company’s interim results announcement, which is expected to be published by the end of November 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 16 November 2023

As at the date of this announcement, the executive Directors are Mr. Shimada Tatsuji, Mr. Miyano Tsumoru, Mr. Maezaki Masahiro, Mr. Haribayashi Keikyo, Mr. Miyazato Hiroki and Mr. Chiu Chun Tak; the non-executive Directors are Mr. Kusaba Takuya and Mr. Yan Ping; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Taguchi Junichi, Mr. Choi Koon Ming and Mr. Saito Hironobu.